Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy
about
Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal DiabetesMitochondrial Metabolism in Aging HeartTGF-β1-mediated differentiation of fibroblasts is associated with increased mitochondrial content and cellular respirationComprehensive metabolic modeling of multiple 13C-isotopomer data sets to study metabolism in perfused working hearts.Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy.MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathyIn vivo proton T1 relaxation times of mouse myocardial metabolites at 9.4 T.The PKD inhibitor CID755673 enhances cardiac function in diabetic db/db miceMetabolic alterations induce oxidative stress in diabetic and failing hearts: different pathways, same outcome.Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal Dilated Cardiomyopathy in Mice.Exogenous spermine ameliorates high glucose-induced cardiomyocytic apoptosis via decreasing reactive oxygen species accumulation through inhibiting p38/JNK and JAK2 pathways.Nutrient-sensing mTORC1: Integration of metabolic and autophagic signalsEffects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyα-MSH and Foxc2 promote fatty acid oxidation through C/EBPβ negative transcription in mice adipose tissue.Ginsenoside Rg5 increases cardiomyocyte resistance to ischemic injury through regulation of mitochondrial hexokinase-II and dynamin-related protein 1Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology.Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models.Impaired Energy Production Contributes to Development of Failure in Taurine Deficient Heart.Hearts lacking plasma membrane KATP channels display changes in basal aerobic metabolic substrate preference and AMPK activity.Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure.A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition.Diabetes-Related Cardiac Dysfunction.Mitochondria as a target of cardioprotection in models of preconditioning.A dose-dependent perturbation in cardiac energy metabolism is linked to radiation-induced ischemic heart disease in Mayak nuclear workers.Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.Non-targeted metabolomics identified a common metabolic signature of lethal ventricular tachyarrhythmia (LVTA) in two rat models.Mitochondrial pharmacology: energy, injury and beyond.Inflexibility of AMPK-mediated metabolic reprogramming in mitochondrial disease.Mitophagy as a Protective Mechanism against Myocardial Stress.Modulation of NFKB1/p50 by ROS leads to impaired ATP production during MI compared to cardiac hypertrophy.Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference and apoptosis.Exercise-Induced Changes in Glucose Metabolism Promote Physiological Cardiac Growth.Integration of miRNA and gene expression profiles suggest a role for miRNAs in the pathobiological processes of acute Trypanosoma cruzi infection.Genetic Dissociation of Glycolysis and the TCA Cycle Affects Neither Normal nor Neoplastic Proliferation.Proteomics landscape of radiation-induced cardiovascular disease: somewhere over the paradigm.Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.Mass-spectrometry-based lipidomics.Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts.Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy.
P2860
Q28354148-8B41160A-50F8-41FA-B413-1C38ACB520F7Q28388306-C1820E55-340C-4E6B-9C93-63598096A2D3Q28545823-D08EDDF8-C1EC-4295-9FCA-75477099489AQ31119881-36CDB1BE-7A42-4CF1-BFCF-9A9B122AD7A6Q33740554-C09A812D-F6D4-46BD-9D1A-458C6FF04EDCQ34541619-5C9D3B1B-56FA-4FEE-8614-FFC4C067CA14Q35194395-F4174FC6-A6D0-4DAD-8293-462C51B10957Q35209408-27821734-054D-429D-A9CC-8E52E38EE8D2Q35667039-714A969C-99FA-4639-BCC3-E6F32D6C9FA8Q36109025-ADD3A10A-0661-4657-8C07-EEF81FEB0434Q36511653-7B39580C-9A2F-4D8D-9641-AB21FBA9D964Q37008888-47B3DB2E-8B60-4AC5-BD67-BFA2C86EF471Q37125983-77C71D8B-F8B0-41DA-BA1D-10768F99E030Q37397352-4B0DC579-F6BC-4762-8908-71E99B78D989Q37745258-78719D56-875A-44A8-8EEF-D32B2B70D499Q38262595-1C93C7B0-11A7-45BB-8608-D8DDBA84E1C0Q38375945-1DE5D58E-1215-4A23-8A8B-7A2A206CC473Q38604339-38A2EF70-4E7C-45A3-A59D-745F70863F39Q38699341-6E88C66E-C17B-4DDF-A319-7B7AB862E262Q38815503-FA0BB998-F711-4427-861E-004C9EE1A853Q39035028-7158D8C6-255E-4762-B9ED-CF567C0D7BB2Q39325799-88486188-E84C-482D-92A6-5889451762E5Q39420123-A82C12FB-5830-492D-8A2D-0DC5DB34CDCAQ39449539-7BC59368-218D-495D-8187-3682ABFF2BF5Q39621874-6B31F4CD-55F1-4A69-9ECD-591B16D3F433Q40039502-051814D3-3E47-45C9-B79F-147A891C1BBAQ40772322-8D4D151A-5FE8-4C89-8FE7-C513BA2EE8B3Q42374835-DFFB5977-8FA1-4F78-AB30-4702CB96E760Q46050003-44EF3892-300C-41F4-A0BE-CAF4BE04537AQ46165815-07E58C1E-5E7B-41B2-84FA-427C8F3B1E41Q46326335-8B3A16D9-386B-4BF9-848E-F3BC46F6F84AQ46610209-E832DF19-5AB9-4F1A-8165-BE14292EE119Q47152616-7517268A-025B-4B7B-BAAE-59EA1A4D3E78Q47158357-62AFF72E-B5EA-4A3A-8016-EB90AABCE462Q47838140-A3D071E3-32BA-466E-B655-5BACE78A8F29Q47868740-0585E54A-6AB5-4493-A9A8-56C9AE4AB53DQ48043450-092FDAD9-D81B-4CA9-9A61-17E8436B3A53Q48054989-35001A91-7D8E-4202-B5E1-CC13F395EAC3Q49917356-C1B5BF7A-A565-41A9-9F87-5949A0E5476CQ49979941-818EF9B9-49FF-47F8-A518-7D499D4B309F
P2860
Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@ast
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@en
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@nl
type
label
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@ast
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@en
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@nl
prefLabel
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@ast
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@en
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@nl
P2093
P2860
P921
P3181
P356
P1476
Mitochondrial fatty acid oxida ...... se and diabetic cardiomyopathy
@en
P2093
P2860
P304
P3181
P356
10.1111/BPH.12475
P407
P577
2014-04-01T00:00:00Z